Plaque Psoriasis research hub

A study to assess the effect of single and repeated doses of JNJ-81241459 on a single dose of certain other drugs, when given together to healthy adult participants

This study looks at how a new medicine, JNJ-81241459, interacts with other common medicines when taken together. It's for healthy adults and helps us understand how drugs might affect each other, which is important for people with skin conditions like plaque psoriasis.

A Phase 2b Multicenter, Randomized, Double-blind, Placebo-controlled Dose-Ranging Study to Evaluate the Efficacy and Safety of JNJ-81241459 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis

This study is looking into a new medicine, JNJ-81241459, for people with moderate to severe plaque psoriasis. We want to see how well different doses work to clear up skin patches and if it's safe. It's a key step in developing new treatments.

Evaluation of Safety, Tolerability, and Pharmacodynamic Effects of Topically Applied SUDO-286 in Psoriasis

This study is testing a new cream called SUDO-286 for plaque psoriasis. We want to see if it's safe to use, how well people tolerate it, and how it affects the body. This is an early study to check its effects in humans.

A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor-blinded-Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects with Moderate Plaque Psoriasis who are Candidates for Systemic Therapy

This study is looking at two medicines, risankizumab and deucravacitinib, for adults with moderate plaque psoriasis. It compares how well they clear up skin and aims to see if switching medicine helps if the first one isn't working as well as hoped.

A phase III, multicentre, randomised, observer-blind, intraindividual, paired, comparative trial to evaluate the efficacy and safety of a 0.1% mometasone furoate cutaneous emulsion compared to Ecural® fat cream and vehicle cutaneous emulsion in the treatment of adult participants with plaque psoriasis

This study is testing a new cream for adults with plaque psoriasis. It compares a new mometasone furoate cream to an existing one and a cream with no medicine, to see how well they reduce psoriasis symptoms and if they are safe.

Immunological and functional characteristics of T memory-like cells in psoriasis under treatment with deucravacitinib - IM011-1115

This study looks at how a new medicine, SOTYKTU, affects certain immune cells (TRM-like cells) in people with plaque psoriasis. Researchers want to see if SOTYKTU helps reduce these cells and their activity over 24 weeks to understand how it treats psoriasis.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous and subcutaneous multiple rising doses of BI 765250 versus placebo in trial participants with moderate to severe plaque psoriasis (double-blind, randomised, placebo-controlled, parallel-group design)

This study is looking at a new medicine called BI 765250 for people with moderate to severe plaque psoriasis. Researchers want to see if it's safe, how the body handles it, and if it helps improve psoriasis, compared to a dummy treatment.

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

This study is looking into a new treatment called JNJ-77242113 for moderate to severe plaque psoriasis in teenagers and adults. We want to see how well it works to improve skin symptoms. It's a Phase 3 trial, meaning it's a key step in testing this potential new medicine.

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis

This study is looking at a new medicine called deucravacitinib for children and teenagers aged 4 to 17 with moderate to severe plaque psoriasis. It aims to understand how much medicine is needed, if it works, and if it's safe to use.

A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

This study is testing a new medicine called TAK-279 for moderate to severe plaque psoriasis. It aims to see how safe the medicine is and how well people tolerate it, building on earlier studies. It involves participants taking the medicine for up to four years.

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

This study is looking at a new medicine, JNJ-77242113, for people with moderate to severe plaque psoriasis. It compares how well it works against a dummy treatment (placebo) and an existing medicine called deucravacitinib.

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

This study compares a new medicine, deucravacitinib, with an existing one, ustekinumab, for long-term safety in people with moderate to severe plaque psoriasis. It focuses on participants who also have heart disease risk factors.

A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

This study is looking at a new medication, JNJ-77242113, for people with moderate to severe plaque psoriasis. It compares the new medication to a widely used treatment (ustekinumab) and a dummy medicine (placebo) to see how safe and effective it is.

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

This study is looking at a new medicine, JNJ-77242113, for people with plaque psoriasis on sensitive areas like the scalp, genitals, or palms and soles. It aims to see if this medicine works better than a dummy treatment.

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of LY4100511 (DC-853) for the Treatment of Adult Participants with Moderate-to-Severe Plaque Psoriasis

This study is testing a new medicine, LY4100511, for adults with moderate to severe plaque psoriasis. It's a Phase 2 trial, meaning it's an early stage to see how well the medicine works and if it's safe, compared to a dummy pill.

A Phase 4 (Phase 2 in European Union), Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-118 Lotion in Pediatric Subjects with Moderate to Severe Plaque Psoriasis

This study is looking at a new lotion called Duobrii for children and teenagers with moderate to severe plaque psoriasis. Doctors want to see how much of the medicine gets into the body, if it's safe to use every day, and how it affects important body functions.

Assessment of the safety and effects on the body of investigational products when used on psoriatic skin

This study is looking at a new treatment for plaque psoriasis. Scientists want to see if it's safe and how it affects the skin. It's a very early-stage study, open to adults with plaque psoriasis, and is designed to understand the treatment better before larger studies begin.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fed condition

This study compares a new version of psoriasis medication from Sun Pharma with the original Sotyktu. It involves healthy adults taking a single dose of each medicine to see if they act the same way in the body after eating.

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fasting condition.

This study is comparing two versions of a medication for plaque psoriasis called deucravacitinib. We want to see if a new generic version works the same way as the original. Healthy adults take both medicines to help us understand. It's about checking if they are equally effective.

A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CAN10, an Anti-IL1RAP Monoclonal Antibody, in Healthy Subjects and in Subjects with Mild to Moderate Plaque Psoriasis

OptIMMize-1: A Randomized, Active-controlled, Efficacy Assessor-blinded Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Risankizumab in Patients From 6 to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-blind, Placebo- controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe Plaque Psoriasis